Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The spread of Influenza H1N1 has prompted the development of vaccines against this virus. IBD patients are at increased risk of developing complications of Influenza H1N1. The efficacy and safety of H1N1 vaccination have not been evaluated in this population of patients. We would like to estimate the efficacy and safety of vaccination against influenza H1N1 in patients with IBD who treated with immunomodulatory drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Safety Study of Flu Vaccine in Immunodepression Patients

NCT01022749

Inflammatory Bowel Disease (IBD)

COMPLETED PHASE3

Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases

NCT05067959

IBD Covid19

UNKNOWN

Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine

NCT00542776

Inflammatory Bowel Disease (IBD) Immunosuppressed or Non-Immunosuppressed Influenza Vaccine +2 more

COMPLETED

Infliximab IBD Influenza Vaccine Study

NCT01666535

Inflammatory Bowel Disease

COMPLETED NA

Flu Vaccine Response in Patients on Biologic Therapies

NCT03277703

Rheumatologic Disorder Inflammatory Bowel Diseases Immune Complex Diseases

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

200 patients with IBD and 200 healthy subjects will participate in the study. All the subjects will be vaccinated with Focetria (Novartis) and will be evaluated the day of vaccination and 4 weeks later.

The evaluation will include:

Efficacy of the vaccine: Blood will be drawn on day 0 and 4 weeks later and tested for the presence of antibodies against A/California17/2009/H1N1 by hemagglutination inhibition test.

Safety of the vaccine:

* Records of adverse event
* Assessment of disease activity : CDAI and MAYO score

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza H1N1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monovalent MF59- Adjuvanted vaccine

Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular

Group Type EXPERIMENTAL

Focetria (Monovalent MF59-Adjuvanted vaccine)

Intervention Type BIOLOGICAL

Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Focetria (Monovalent MF59-Adjuvanted vaccine)

Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients suffering from IBD (inflammatory bowel disease): UC/ CD
2. Able to firm an informed consent
3. Aged - 18-65
4. Candidates to receive vaccination against H1N1, according to the recommendation of the Ministry of Health
5. patients who treated with immunomodulators and biologics

Exclusion Criteria

1. Allergy to eggs
2. Known allergy to seasonal influenza vaccine
3. Pregnant women
4. Patients who inoculate another vaccine in the past 3 weeks (except vaccine fot seasonal influenza
5. Patients without worsening in their disease condition (stable condition)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes